ARTIFICIAL INTELLIGENCE
FOR DRUG DISCOVERY,
BIOMARKER DEVELOPMENT &
AGING RESEARCH
Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research.
We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Our latest publication in Nature Biotechnology
AI Pharma Pipeline
We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules that already exist or can be generated
de novo with the desired set of parameters.
Over 150 Academic
and Industry Collaborators Worldwide

We have a great pleasure to work with the leading companies and institutions
to provide next-level solutions for drug discovery and biomarker development.
We have over 85 scientists hired through hackathons and competitions worldwide in the US, UK, Poland, Belgium, South Korea, Taiwan, Africa and Russia.
Our Publications
Special issue in American Chemical Society's Molecular Pharmaceutics mostly dedicated to GANs and molecules
Generative adversarial networks and deep reinforcement learning techniques are propagating into the many areas of pharmaceutical R&D, learning and augmenting human abilities.
Upcoming Conferences
BioDataWorld Congress 2019
December 4-5, 2019 | Basel, Switzerland
Conference Website
NeurIPS 2019
December 8-14, 2019 | Vancouver, Canada
Conference Website
FierceBiotech Executive Breakfast & Panel Discussions at the 38th Annual J.P. Morgan Healthcare Conference
January 13-16, 2020 | San Francisco, California
Track the news on
Contact us:
Insilico Medicine

307A, Core Building 1, 1 Science Park East Avenue, Hong Kong Science Park,
Pak Shek Kok, Hong Kong


Email: zhu@insilicomedicine.com